Literature DB >> 29097328

Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model.

Leeyup Chung1, Alexandra L Bey2, Aaron J Towers3, Xinyu Cao1, Il Hwan Kim4, Yong-Hui Jiang5.   

Abstract

Epilepsy is prevalent and often medically intractable in Angelman syndrome (AS). AS mouse model (Ube3am-/p+) shows reduced excitatory neurotransmission but lower seizure threshold. The neural mechanism linking the synaptic dysfunction to the seizure remains elusive. We show that the local circuits of Ube3am-/p+in vitro are hyperexcitable and display a unique epileptiform activity, a phenomenon that is reminiscent of the finding in fragile X syndrome (FXS) mouse model. Similar to the FXS model, lovastatin suppressed the epileptiform activity and audiogenic seizures in Ube3am-/p+. The in vitro model of Ube3am-/p+ is valuable for dissection of neural mechanism and epilepsy drug screening in vivo.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angelman syndrome; Long burst; Lovastatin; Seizure; Ube3a

Mesh:

Substances:

Year:  2017        PMID: 29097328      PMCID: PMC5903876          DOI: 10.1016/j.nbd.2017.10.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  62 in total

1.  Genetically Dissecting Cortical Neurons Involved in Epilepsy in Angelman Syndrome.

Authors:  Emanuela Santini; Eric Klann
Journal:  Neuron       Date:  2016-04-06       Impact factor: 17.173

2.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

3.  Cav 1.3 channels play a crucial role in the formation of paroxysmal depolarization shifts in cultured hippocampal neurons.

Authors:  Victoria Stiglbauer; Matej Hotka; Manuel Ruiß; Karlheinz Hilber; Stefan Boehm; Helmut Kubista
Journal:  Epilepsia       Date:  2017-03-11       Impact factor: 5.864

Review 4.  Molecular signaling mechanisms underlying epileptogenesis.

Authors:  James O McNamara; Yang Zhong Huang; A Soren Leonard
Journal:  Sci STKE       Date:  2006-10-10

5.  UBE3A Regulates Synaptic Plasticity and Learning and Memory by Controlling SK2 Channel Endocytosis.

Authors:  Jiandong Sun; Guoqi Zhu; Yan Liu; Steve Standley; Angela Ji; Rashmi Tunuguntla; Yubin Wang; Chad Claus; Yun Luo; Michel Baudry; Xiaoning Bi
Journal:  Cell Rep       Date:  2015-07-09       Impact factor: 9.423

Review 6.  Neurologic manifestations of Angelman syndrome.

Authors:  Ronald L Thibert; Anna M Larson; David T Hsieh; Annabel R Raby; Elizabeth A Thiele
Journal:  Pediatr Neurol       Date:  2013-04       Impact factor: 3.372

7.  Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.

Authors:  Andreas Bergdahl; Erik Persson; Per Hellstrand; Karl Swärd
Journal:  Pharmacol Toxicol       Date:  2003-09

8.  Aberrant somatosensory-evoked responses imply GABAergic dysfunction in Angelman syndrome.

Authors:  Kiyoshi Egawa; Naoko Asahina; Hideaki Shiraishi; Kyousuke Kamada; Fumiya Takeuchi; Shingo Nakane; Akira Sudo; Shinobu Kohsaka; Shinji Saitoh
Journal:  Neuroimage       Date:  2007-09-15       Impact factor: 6.556

9.  Persistent receptor activity underlies group I mGluR-mediated cellular plasticity in CA3 neuron.

Authors:  Steven R Young; Shih-Chieh Chuang; Wangfa Zhao; Robert K S Wong; Riccardo Bianchi
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

Review 10.  Statins - are they anticonvulsant?

Authors:  Monika Banach; Stanisław J Czuczwar; Kinga K Borowicz
Journal:  Pharmacol Rep       Date:  2014-04-26       Impact factor: 3.024

View more
  8 in total

Review 1.  Epilepsy in Angelman syndrome: A scoping review.

Authors:  Debopam Samanta
Journal:  Brain Dev       Date:  2020-09-04       Impact factor: 1.961

2.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

3.  The Effect of Statins in Epilepsy: A Systematic Review.

Authors:  Loraine De Jesús Quintana-Pájaro; Yancarlos Ramos-Villegas; Eileen Cortecero-Sabalza; Andrei F Joaquim; Amit Agrawal; Alexis Rafael Narvaez-Rojas; Luis Rafael Moscote-Salazar
Journal:  J Neurosci Rural Pract       Date:  2018 Oct-Dec

4.  Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse.

Authors:  Vipendra Kumar; Tripti Joshi; Naman Vatsa; Brijesh Kumar Singh; Nihar Ranjan Jana
Journal:  Front Mol Neurosci       Date:  2019-11-26       Impact factor: 5.639

5.  Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.

Authors:  N A Copping; J L Silverman
Journal:  Mol Autism       Date:  2021-02-06       Impact factor: 7.509

6.  Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency.

Authors:  Anna Adhikari; Fiona K B Buchanan; Timothy A Fenton; David L Cameron; Julian A N M Halmai; Nycole A Copping; Kyle D Fink; Jill L Silverman
Journal:  Hum Mol Genet       Date:  2022-09-10       Impact factor: 5.121

7.  A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders.

Authors:  Melania Muscas; Sang S Seo; Susana R Louros; Emily K Osterweil
Journal:  eNeuro       Date:  2020-08-13

Review 8.  Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.

Authors:  Nycole A Copping; Stephanie M McTighe; Kyle D Fink; Jill L Silverman
Journal:  Neurotherapeutics       Date:  2021-09-15       Impact factor: 7.620

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.